Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324608 · ClinicalTrials.gov registry record · NA
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT02324608 is a NA study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 15 participants.
The verdict
NCT02324608, a NA study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects and how well cetuximab before surgery works in treating patients with skin cancer that forms, grows, and spreads quickly and has spread from where it started to nearby tissue or lymph nodes. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways be targeting certain cells. Giving cetuximab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-01-30 |
| Est. Completion | 2023-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02324608
The ClinicalTrials.gov registry entry for NCT02324608 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02324608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02324608 about?
NCT02324608 is a clinical study titled "Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer". This pilot clinical trial studies the side effects and how well cetuximab before surgery works in treating patients with skin cancer that forms, grows, and spreads quickly and has spread from where it started to nearby tissue or lymph nodes. Monoclonal antibodies, such as cetuximab, may block tumor ...
What is the current status of trial NCT02324608?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2015-01-30. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT02324608?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02324608?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.